Figure 2.
Incremental costs and health benefits of strategies compared to the status quo. Incremental costs and health benefits are per 1000 children initiating ART over a 10-year time horizon. No incremental cost-effectiveness ratio (ICER) was calculated for pretreatment drug resistance (PDR) testing because it was dominated by improved switching (PDR testing gained fewer life years (LYs) at a greater cost compared to improved switching).